首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >A CLINICAL STUDY ON SAFETY AND EFFICACY OF FORMOTEROL AND TIOTROPIUM COMBINATION COMPARED TO FORMOTEROL AND TIOTROPIUM WITH ROFLUMILAST COMBINATION IN TREATMENT OF MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS
【24h】

A CLINICAL STUDY ON SAFETY AND EFFICACY OF FORMOTEROL AND TIOTROPIUM COMBINATION COMPARED TO FORMOTEROL AND TIOTROPIUM WITH ROFLUMILAST COMBINATION IN TREATMENT OF MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS

机译:甲酚和噻托溴铵与甲酚和噻托溴铵联用氟鲁司特合治疗中重度慢性阻塞性肺疾病的安全性和有效性的临床研究

获取原文
       

摘要

Objectives : The objective of this study is to assess the safety and efficacy of formoterol and tiotropium combination compared to formoterol and tiotropium with roflumilast combination in treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) patients on inhaled combination therapy. Methods: A comparative prospective interventional study was carried out in 61 COPD patients who were visiting the pulmonary medicine ward during 6 months (October 2016 to March 2017). The patients were randomized into two groups. Group A patients received a combination of formoterol and tiotropium, whereas Group B patients received roflumilast along with formoterol and tiotropium combination. Spirometry tests were done to both the study population. Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were noted at the initial visit and after the treatment. All the statistical analyses such as mean and p values were calculated using SPSS 14.0 version software. Results: The average age group of the study population was 57.63±8.3 years. Comorbid condition such as diabetes mellitus was higher in the study groups. Comparison of spirometry reports before and after drug administration in both groups was done. FEV1 and FVC were found to be statistically significant between the study group (0.001, p<0.05).The average mean change of FEV1 before and after treatment in Group B was found to be improved as compared to Group B (0.66). Conclusion: Tiotropium and formoterol with roflumilast combination were found to be safe and effective in moderate-to-severe COPD patients.
机译:目的:本研究的目的是评估福莫特罗和噻托溴铵联用与福莫特罗和噻托溴铵联合罗氟司特联合治疗中重度慢性阻塞性肺疾病(COPD)吸入联合治疗的安全性和有效性。方法:对61例在6个月内(2016年10月至2017年3月)就诊于肺科病房的COPD患者进行了一项比较前瞻性干预研究。将患者随机分为两组。 A组患者接受了福莫特罗和噻托溴铵的联合治疗,而B组患者接受了罗氟司特以及福莫特罗和噻托溴铵的联合治疗。对两个研究人群均进行了肺活量测定测试。在初次就诊时和治疗后,记录了1秒钟的强制呼气量(FEV1)和强制肺活量(FVC)。使用SPSS 14.0版本软件计算所有统计分析,例如平均值和p值。结果:研究人群的平均年龄为57.63±8.3岁。在研究组中,合并症如糖尿病较高。两组在给药前后的肺活量测定报告进行了比较。研究组之间FEV1和FVC的差异具有统计学意义(0.001,p <0.05).B组治疗前后FEV1的平均平均变化较B组(0.66)有所改善。结论:噻托溴铵和福莫特罗联合罗氟司特对中重度COPD患者是安全有效的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号